Alexion receives marketing authorisation from European Commission for new formulation of Ultomiris (ravulizumab) with significantly reduced infusion time

Alexion Pharmaceuticals

20 November 2020 - The new 100 mg/mL formulation will reduce infusion time by approximately 60%, lessening the burden on patients.

Alexion Pharmaceuticals today announced that the European Commission has approved the new 100 mg/mL intravenous formulation of Ultomiris (ravulizumab) for the treatment of two ultra-rare diseases – paroxysmal nocturnal hemoglobinuria and atypical haemolytic uraemic syndrome.

Read Alexion Pharmaceuticals press release

Michael Wonder

Posted by:

Michael Wonder

Posted in:

Outcome , Medicine , Europe